European regulators have endorsed Imfinzi as part of a perioperative treatment strategy that significantly reduces recurrence and death in early-stage gastric and gastroesophageal junction cancer.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/ema-backs-immunotherapy-early-gastric-and-gej-cancers-2026a10003cp?src=rss
Author :
Publish date : 2026-02-03 13:48:00
Copyright for syndicated content belongs to the linked Source.